6-溴-2,4-二氯-8-甲基喹唑啉 | 1039736-74-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 6-溴-2,4-二氯-8-甲基喹唑啉
• 英文名称: 6-bromo-2,4-dichloro-8-methylquinazoline
• 英文别名: 6-Bromo-2,4-dichloro-8-methylquinazoline
• CAS: 1039736-74-7
• 化学式: C₉H₅BrCl₂N₂
• 分子量: 291.962
• InChiKey: CIUHQDCEPALBLE-UHFFFAOYSA-N

物化性质

• 沸点：
  347.5±24.0 °C(Predicted)
• 密度：
  1.755±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-溴-2,4-二氯-8-甲基喹唑啉 在 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 32.0h， 生成 N-[4-({[6-bromo-8-methyl-2-(methylamino)quinazolin-4-yl]amino}methyl)phenyl]-4-chlorobenzamide
  参考文献：
  名称：

  WO2008/86462

  摘要：

  公开号：
• 作为产物：
  描述：

  2-氨基-5-溴-3-甲基苯甲酸 在 N,N-二异丙基乙胺 、 三氯氧磷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 28.0h， 生成 6-溴-2,4-二氯-8-甲基喹唑啉
  参考文献：
  名称：

  [EN] QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS
  [FR] QUINAZOLINES ET AZAQUINAZOLINES EN TANT QUE DOUBLES INHIBITEURS DES VOIES RAS/RAF/MEK/ERK ET PI3K/AKT/PTEN/MTOR

  摘要：

  本申请提供了新型喹唑啉和氮杂喹唑啉及其药用可接受盐。还提供了制备这些化合物的方法。通过向患者投与式有效量的式(I)化合物中的一个或多个，其中X、Y、T和R4，以及R6到R8'在此处定义，来共同调节RAS/RAF/MEK/ERK和PI3K/AKT/PTEN/mTOR途径。通过这样做，这些化合物在治疗与RAS/RAF/MEK/ERK和PI3K/AKT/PTEN/mTOR途径失调相关的疾病方面是有效的。可以使用这些化合物治疗各种疾病，包括以异常细胞增殖为特征的疾病。在一个实施例中，该疾病是癌症。

  公开号：

  WO2014169167A1

文献信息

• AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF BETA-CATENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS
  申请人：VENKATESAN Aranapakam M.

  公开号：US20090004185A1

  公开（公告）日：2009-01-01

  The present invention relates to amino-substituted quinazoline derivatives as inhibitors of β-catenin/tcf-4 pathway, which can be useful in the treatment of cancer; to processes for their preparation; to pharmaceutical compositions comprising them; and to methods of using them.

  本发明涉及氨基取代的喹唑啉衍生物，作为β-连环蛋白/TCF-4途径的抑制剂，可用于癌症治疗；涉及其制备方法；涉及包含它们的制药组合物；以及使用它们的方法。
• QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS
  申请人：ASANA BIOSCIENCES, LLC

  公开号：US20160068496A1

  公开（公告）日：2016-03-10

  The present application provides novel quinazolines and azaquinazolines and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in for co-regulating RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways by administering a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, T and R 4 , and R 6 to R 8′ are defined herein, to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment/the disease is cancer.

  本申请提供了新型的喹唑啉和氮杂喹唑啉及其药学上可接受的盐。还提供了制备这些化合物的方法。通过向患者投予公式（I）中的一个或多个化合物的治疗有效量，其中X、Y、T和R4以及R6到R8'在此定义，这些化合物在共同调节RAS / RAF / MEK / ERK和PI3K / AKT / PTEN / mTOR途径方面是有用的。通过这样做，这些化合物对治疗与RAS / RAF / MEK / ERK和PI3K / AKT / PTEN / mTOR途径失调有关的疾病具有有效性。这些化合物可用于治疗多种疾病，包括以异常细胞增殖为特征的疾病。在一个实施例中，该疾病是癌症。
• Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways
  申请人：Asana BioSciences, LLC

  公开号：US10226468B2

  公开（公告）日：2019-03-12

  The present application provides novel quinazolines and azaquinazolines and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in for co-regulating RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways by administering a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, T and R4, and R6 to R8′ are defined herein, to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer.

  本申请提供了新型喹唑啉类和偶氮喹唑啉类化合物及其药学上可接受的盐类。还提供了制备这些化合物的方法。通过向患者施用治疗有效量的一种或多种式(I)化合物，其中X、Y、T和R4以及R6至R8′在本文中定义，这些化合物可用于共同调节RAS/RAF/MEK/ERK和PI3K/AKT/PTEN/mTOR通路。这样，这些化合物就能有效治疗与 RAS/RAF/MEK/ERK 和 PI3K/AKT/PTEN/mTOR 通路失调有关的疾病。使用这些化合物可以治疗多种疾病，包括以细胞异常增殖为特征的疾病。在一个实施方案中，疾病是癌症。
• Discovery, Synthesis, and Biological Evaluation of Thiazoloquin(az)olin(on)es as Potent CD38 Inhibitors
  作者：Curt D. Haffner、J. David Becherer、Eric E. Boros、Rodolfo Cadilla、Tiffany Carpenter、David Cowan、David N. Deaton、Yu Guo、Wallace Harrington、Brad R. Henke、Michael R. Jeune、Istvan Kaldor、Naphtali Milliken、Kim G. Petrov、Frank Preugschat、Christie Schulte、Barry G. Shearer、Todd Shearer、Terrence L. Smalley、Eugene L. Stewart、J. Darren Stuart、John C. Ulrich

  DOI：10.1021/jm502009h

  日期：2015.4.23

  A series of thiazoloquin(az)olinones were synthesized and found to have potent inhibitory activity against CD38. Several of these compounds were also shown to have good pharmacokinetic properties and demonstrated the ability to elevate NAD levels in plasma, liver, and muscle tissue. In particular, compound 78c was given to diet induced obese (DIO) C57Bl6 mice, elevating NAD > 5-fold in liver and >1.2-fold in muscle versus control animals at a 2 h time point. The compounds described herein possess the most potent CD38 inhibitory activity of any small molecules described in the literature to date. The inhibitors should allow for a more detailed assessment of how NAD elevation via CD38 inhibition affects physiology in NAD deficient states.
• COMPOUNDS WHICH SPECIFICALLY BIND TO CD38 FOR USE IN THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES
  申请人：ENCEFA

  公开号：US20210087290A1

  公开（公告）日：2021-03-25

  A compound, which specifically binds to CD38, for use as a medicament in the prevention and/or treatment of a neurodegenerative disease and/or an inflammatory disease, by the opening of NAADP receptors Two Pore Channels TPC1 and/or TPC2, wherein the compound activates the opening of NAADP receptors Two Pore Channels TPC1 and/or TPC2.